News
ICCC
10.19
-0.68%
-0.07
Weekly Report: what happened at ICCC last week (1102-1106)?
Weekly Report · 2d ago
Weekly Report: what happened at ICCC last week (1026-1030)?
Weekly Report · 11/02 10:12
Weekly Report: what happened at ICCC last week (1019-1023)?
Weekly Report · 10/26 10:11
Weekly Report: what happened at ICCC last week (1012-1016)?
Weekly Report · 10/19 10:11
ImmuCell reports Q3 preliminary results
Seeking Alpha · 10/14 15:16
ImmuCell Reports Preliminary Q3 2026 Sales Growth Of 46%;Stock Up
NASDAQ · 10/13 07:21
Closing Bell Movers: Navitas gains on Nvidia collaboration
TipRanks · 10/12 23:30
ImmuCell Sees Q3 Sales $8.000M
Benzinga · 10/12 20:25
Immucell reports preliminary Q3 revenue $8M
TipRanks · 10/12 20:15
ImmuCell Reports Q3 Preliminary Sales Of $8M, Up 46% YoY
Benzinga · 10/12 20:06
Weekly Report: what happened at ICCC last week (1005-1009)?
Weekly Report · 10/12 10:16
Weekly Report: what happened at ICCC last week (0928-1002)?
Weekly Report · 10/05 10:16
The Zacks Analyst Blog Highlights Alphabet, Mastercard, AbbVie, Perma-Pipe and ImmuCell
NASDAQ · 09/29 06:23
Top Research Reports for Alphabet, Mastercard & AbbVie
NASDAQ · 09/28 19:49
Weekly Report: what happened at ICCC last week (0921-0925)?
Weekly Report · 09/28 10:11
SRK Capital 2026 Semi-Annual Portfolio Update
Seeking Alpha · 09/21 10:30
Weekly Report: what happened at ICCC last week (0914-0918)?
Weekly Report · 09/21 10:12
Weekly Report: what happened at ICCC last week (0907-0911)?
Weekly Report · 09/14 10:16
Weekly Report: what happened at ICCC last week (0831-0904)?
Weekly Report · 09/07 10:10
Weekly Report: what happened at ICCC last week (0824-0828)?
Weekly Report · 08/31 10:17
More
Webull provides a variety of real-time ICCC stock news. You can receive the latest news about Immucell through multiple platforms. This information may help you make smarter investment decisions.
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).